排序方式: 共有25条查询结果,搜索用时 0 毫秒
1.
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047
Wen-Lin Kuo Debopriya Das Safiyyah Ziyad Sanchita Bhattacharya William J Gibb Laura M Heiser Anguraj Sadanandam Gerald V Fontenay Zhi Hu Nicholas J Wang Nora Bayani Heidi S Feiler Richard M Neve Andrew J Wyrobek Paul T Spellman Laurence J Marton Joe W Gray 《BMC medicine》2009,7(1):1-11
Background
When this trial was initiated, the combined measles, mumps and rubella (MMR) vaccine was licensed for subcutaneous administration in all European countries and for intramuscular administration in some countries, whereas varicella vaccine was licensed only for subcutaneous administration. This study evaluated the intramuscular administration of an MMR vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) compared with the subcutaneous route.Methods
An open-label randomised trial was performed in France and Germany. Healthy children, aged 12 to18 months, received single injections of M-M-RvaxPro and VARIVAX concomitantly at separate injection sites. Both vaccines were administered either intramuscularly (IM group, n = 374) or subcutaneously (SC group, n = 378). Immunogenicity was assessed before vaccination and 42 days after vaccination. Injection-site erythema, swelling and pain were recorded from days 0 to 4 after vaccination. Body temperature was monitored daily between 0 and 42 days after vaccination. Other adverse events were recorded up to 42 days after vaccination and serious adverse events until the second study visit.Results
Antibody response rates at day 42 in the per-protocol set of children initially seronegative to measles, mumps, rubella or varicella were similar between the IM and SC groups for all four antigens. Response rates were 94 to 96% for measles, 98% for both mumps and rubella and 86 to 88% for varicella. For children initially seronegative to varicella, 99% achieved the seroconversion threshold (antibody concentrations of ≥ 1.25 gpELISA units/ml). Erythema and swelling were the most frequently reported injection-site reactions for both vaccines. Most injection-site reactions were of mild intensity or small size (≤ 2.5 cm). There was a trend for lower rates of injection-site erythema and swelling in the IM group. The incidence and nature of systemic adverse events were comparable for the two routes of administration, except varicella-like rashes, which were less frequent in the IM group.Conclusion
The immunogenicities of M-M-RvaxPro and VARIVAX administered by the intramuscular route were comparable with those following subcutaneous administration, and the tolerability of the two vaccines was comparable regardless of administration route. Integration of both administration routes in the current European indications for the two vaccines will now allow physicians in Europe to choose their preferred administration route in routine clinical practice.Trial registration
ClinicalTrials.gov NCT00432523 相似文献2.
Synthesis and Pharmacology of N-Benzylidene Derivatives A series of new derivatives of N-(benzylidene)anthranilic acid and 4-(benzylideneamino)benzoic acid have been synthesized and tested for their pharmacologic activities in animals. Marked anti-inflammatory, hypotensive and analgesic activities were observed. Some compounds also decrease the motorial activity. An attempt has been made to evaluate structure-activity relationships in this series. 相似文献
3.
Srinivas Nayak Amgoth Mahendar Porika Sadanandam Abbagani Achaiah Garlapati Malla Reddy Vanga 《Medicinal chemistry research》2013,22(1):147-155
Fourteen new 4-alkyl/aryl-3,5-bis-(carboethoxy/carbomethoxy)-1,4-dihydro-2,6-dimethylpyridines (4a–4n) have been prepared by conventional and microwave irradiation (MWI) methods from a three component reaction mixture viz., alkyl acetoacetate (1), appropriate aldehyde (2) and ammonium acetate (3). The compounds prepared have been purified and characterized by their spectral (FTIR, 1H NMR and MS) data. The two synthetic methods employed have been compared in terms of relative yields and reaction times. On comparison, the MWI method has been found to be easy, simple, eco-friendly, rapid and high yielding. The synthesized compounds have been evaluated for their cytotoxic activity against HT-29 (colon cancer) and MDA-MB (breast cancer) cell lines and MRP1 inhibitory activity using the insect cell membrane MRP 1 ATPase assay. Though some of the compounds could exhibit some degree of cytotoxicity it was found to be low in comparison to standard. Among the compounds tested 4g was relatively better in its MRP1 inhibitory action (IC50 = 16 μM) but not comparable to that of benzbromarone (IC50 = 4 μM). 相似文献
4.
Elisa Fontana Krisztian Homicsko Katherine Eason Anguraj Sadanandam 《Current colorectal cancer reports》2016,12(6):296-302
Although surgery for early-stage colorectal cancer (CRC) is often curative, many patients require adjuvant chemotherapy to treat micrometastatic disease and to reduce the risk of recurrence. Targeted therapies have improved outcomes for patients with metastatic disease but, in the adjuvant setting, options are limited to a fluoropyrimidine alone or in combination with oxaliplatin. There is an unmet need for new predictive biomarkers to personalise treatment in the adjuvant setting. With goals to address this gap and to better characterise disease heterogeneity, several groups including our own have identified three to six gene expression subtypes that were later consolidated into consensus molecular subtypes as part of the Colorectal Cancer Subtyping Consortium (CRCSC) effort. In this review, we discuss the differences and similarities between these subtypes and their potential prognostic and predictive values. We question whether a personalised treatment approach based on CRC subtypes might be beneficial in the adjuvant setting to improve treatment options and ultimately patient outcomes. 相似文献
5.
A Sadanandam SS Sidhu S Wullschleger S Singh ML Varney CS Yang AE Ashour SK Batra RK Singh 《British journal of cancer》2012,107(3):501-507
Background:
Our earlier reports demonstrated that membrane-bound semaphorin 5A (SEMA5A) is expressed in aggressive pancreatic cancer cells and tumours, and promotes tumour growth and metastasis. In this study, we examine whether (1) pancreatic cancer cells secrete SEMA5A and (2) that secreted SEMA5A modulates certain phenotypes associated with tumour progression, angiogenesis and metastasis through various other molecular factors and signalling proteins.Methods and results:
In this study, we show that human pancreatic cancer cell lines secrete the extracellular domain (ECD) of SEMA5A (SEMA5A-ECD) and overexpression of mouse Sema5A-ECD in Panc1 cells (not expressing SEMA5A; Panc1-Sema5A-ECD; control cells - Panc1-control) significantly increases their invasion in vitro via enhanced ERK phosphorylation. Interestingly, orthotopic injection of Panc1-Sema5A-ECD cells into athymic nude mice results in a lower primary tumour burden, but enhances the micrometastases to the liver as compared with Panc1-control cells. Furthermore, there is a significant increase in proliferation of endothelial cells treated with conditioned media (CM) from Panc1-Sema5A-ECD cells and a significant increase in microvessel density in Panc1-Sema5A-ECD orthotopic tumours compared with those from Panc1-control cells, suggesting that the increase in liver micrometastases is probably due to increased tumour angiogenesis. In addition, our data demonstrate that this increase in endothelial cell proliferation by Sema5A-ECD is mediated through the angiogenic molecules – interleukin-8 and vascular endothelial growth factor.Conclusion:
Taken together, these results suggest that a bioactive, secreted form of Sema5A-ECD has an intriguing and potentially important role in its ability to enhance pancreatic tumour invasiveness, angiogenesis and micrometastases. 相似文献6.
7.
8.
S Singh K C Nannuru A Sadanandam M L Varney R K Singh 《British journal of cancer》2009,100(10):1638-1646
The aggressiveness of malignant melanoma is associated with differential expression of CXCL-8 and its receptors, CXCR1 and CXCR2. However, the precise functional role of these receptors in melanoma progression remains unclear. In this study, we investigate the precise functional role of CXCR1 and CXCR2 in melanoma progression. CXCR1 or CXCR2 were stably overexpressed in human melanoma cell lines, SBC-2 (non-tumourigenic) and A375P (low-tumourigenic) exhibiting low endogenous expression of receptors. Functional assays were performed to study the resulting changes in cell proliferation, motility and invasion, and in vivo tumour growth using a mouse xenograft model. Our data demonstrated that CXCR1- or CXCR2-overexpressing SBC-2 and A375P melanoma cells had enhanced proliferation, chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2 overexpression in SBC-2 cells induced tumourigenicity, and A375P cells significantly enhanced tumour growth as examined in vivo. Immunohistochemical analyses showed significantly increased tumour cell proliferation and microvessel density and reduced apoptosis in tumours generated from CXCR1- or CXCR2-overexpressing melanoma cells. CXCR1- or CXCR2-induced modulation of melanoma cell proliferation and migration was observed to be mediated through the activation of ERK1/2 phosphorylation. Together, these studies demonstrate that CXCR1 and CXCR2 play essential role in growth, survival, motility and invasion of human melanoma. 相似文献
9.
Mitsuru Futakuchi Kalyan C. Nannuru Michelle L. Varney Anguraj Sadanandam Kimihisa Nakao Kiyofumi Asai Tomoyuki Shirai Shin-ya Sato Rakesh K. Singh 《Cancer science》2009,100(1):71-81
Understanding the cellular and molecular changes in the bone microenvironment is important for developing novel therapeutics to control breast cancer bone metastasis. Although the underlying mechanism(s) of bone metastasis has been the focus of intense investigation, relatively little is known about complex molecular interactions between malignant cells and bone stroma. Using a murine syngeneic model that mimics osteolytic changes associated with human breast cancer, we examined the role of tumor–bone interaction in tumor-induced osteolysis and malignant growth in the bone microenvironment. We identified transforming growth factor-β receptor 1 (TGF-βRI) as a commonly upregulated gene at the tumor-bone (TB) interface. Moreover, TGF-βRI expression and activation, analyzed by nuclear localization of phospho-Smad2, was higher in tumor cells and osteoclasts at the TB interface as compared to the tumor-alone area. Furthermore, attenuation of TGF-β activity by neutralizing antibody to TGF-β or TGF-βRI kinase inhibitor reduced mammary tumor-induced osteolysis, TGF-βRI expression and its activation. In addition, we demonstrate a potential role of TGF-β as an important modifier of receptor activator of NF-κB ligand (RANKL)-dependent osteoclast activation and osteolysis. Together, these studies demonstrate that inhibition of TGF-βRI signaling at the TB interface will be a therapeutic target in the treatment of breast cancer-induced osteolysis. ( Cancer Sci 2009; 100: 71–81) 相似文献
10.
E A Ottesen V Vijayasekaran V Kumaraswami S V Perumal Pillai A Sadanandam S Frederick R Prabhakar S P Tripathy 《The New England journal of medicine》1990,322(16):1113-1117
Ivermectin is a new antifilarial drug that can be given in a single oral dose. To compare the efficacy and side effects of ivermectin with those of diethylcarbamazine, the standard antifilarial treatment, we conducted a randomized, double-blind trial in 40 South Indian men with lymphatic filariasis caused by Wuchereria bancrofti. Patients were randomly assigned to one of three treatments: a single low dose of ivermectin (mean [+/- SE], 21.3 +/- 0.7 micrograms per kilogram of body weight; n = 13) followed by placebo for 12 days; a single high dose of ivermectin (mean, 126.2 +/- 3.7 micrograms per kilogram; n = 13) followed by placebo for 12 days; or diethylcarbamazine for 13 days (6 mg per kilogram per day for 12 days preceded by 3 mg per kilogram for 1 day; n = 14). Eleven patients were initially assigned to receive placebo and after five days were reassigned to one of the three treatment groups. At day 12 there was complete clearance of microfilariae from the blood in all 26 men who took ivermectin and in 11 of the 14 men who took diethylcarbamazine. At six months the numbers of detectable microfilariae (as a percentage of the pretreatment values) were 18.3 percent after low-dose ivermectin and 19.5 percent after high-dose ivermectin, as compared with 6.0 percent after diethylcarbamazine (P less than 0.05). The side effects were confined to the first five days and were similar in the three treatment groups. We conclude that in lymphatic filariasis, the clinical response to a single dose of ivermectin compares favorably with that after the standard 12-day course of diethylcarbamazine. Given the practical advantages of single-dose administration, ivermectin should become a useful medication for the control of bancroftian filariasis. 相似文献